# Final Portfolio Evidence Pack — working draft

## Executive case

ContinuumOS is a hypothetical orchestration overlay for diagnostic closure: result available → clinician acknowledgement → human follow-up direction → referral handoff → next-step confirmation or documented exception. It is not an EHR replacement.

The local prototype demonstrates one approved synthetic tracer, with human clinical, referral, response and closure gates. Its portfolio value is the evidence trail: requirements, decision rights, safety controls, test evidence and explicit limits.

## Evidence status

| Evidence type | Recorded evidence | What it does not establish |
|---|---|---|
| Design | Sprint 1–5 product, workflow, requirements and architecture baseline | Real-world need, adoption or outcomes |
| Prototype and test | Sprint 6B: 79 Node tests, lint, Vite build, clean-session browser regression and Release 0.2 conditional go | Clinical validation, deployment or live integration |
| Synthetic pilot | Sprint 7: 20 controlled runs of one tracer; all passed; four browser-observed actions took 0.311–0.748 seconds | 20 unique episodes, human task time, SLA, AI quality or production performance |
| Reviewer evidence | Not yet recorded | User research, evidence-driven product changes or roadmap reprioritisation |

## BA evidence

- Requirements baseline and traceability: Sprint 5 requirements register and RTM; Sprint 6 scenario and UAT evidence.
- Process and decision rights: explicit state, owner, next action and separate human authority for clinical direction, referral routing, receiving response and closure.
- Risk and governance: Sprint 6 hazard register, defect log, release decision and known-limitations record.
- Pilot control: `synthetic_pilot_dataset_and_method.md` and `pilot_result_summary.csv` distinguish scripted runs from operational performance.

## AI PM evidence

AI-01 and AI-02 are source-linked drafts only. They cannot diagnose, acknowledge, select direction, approve, route, accept, reject, confirm or close work. The prototype supports authorised accept, correct with rationale, reject/discard and manual fallback; its recorded current/stale/unavailable fixture evidence is not a deployed-model evaluation.

## Safety decision: wrong patient or encounter attachment

`SAFE-01` treats uncertain linkage as a Critical risk. Prevention is verified Patient, Encounter and event references; detection is reconciliation and exception evidence; recovery preserves the last verified state and routes work to an Identity reconciliation reviewer. The accepted cost is visible interruption and manual verification rather than silent attachment. Executed evidence covers synthetic missing-encounter quarantine and recovery only. Real MPI behaviour, error prevalence and harm are unresolved.

## Current delivery position

Release 0.2 has a Product Owner Conditional Go for structured synthetic review and synthetic workflow evaluation only. The Sprint 7 pilot found no evidence-supported product change, so the change-evidence table remains unpopulated and revision work is deferred pending structured reviewer feedback.

## Open evidence needed

Three or more documented structured reviews, an evidence-backed product decision/change, and final interview packaging are still required before Sprint 7 can close. Subgroup fairness, production adversarial security, external-model supplier assurance, clinical validation and operational performance remain outside the completed evidence.
